|
Market Closed -
Euronext Paris
11:55:00 2026-10-01 EDT
|
5-day change | 1st Jan Change | ||
| 19.85 EUR | -0.75% |
|
+0.76% | -34.49% |
| 09-17 | Boiron SA Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-22 | Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Business description: BOIRON
Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin.
There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties).
BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries.
Net sales are distributed geographically as follows: France (43.5%), Europe (24%), North America (27.5%) and other (5%).
Number of employees: 2,623
Sales by Activity: BOIRON
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Manufacture and Marketing of Homeopathic Medicines & Other Healthcare Solutions | 455M | 534M | 493M | 488M | 501M |
Geographical breakdown of sales: BOIRON
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
France | 327M | 395M | 342M | 341M | 344M |
North America | 83.91M | 121M | 121M | 126M | 138M |
Europe (excluding France) | 112M | 126M | 123M | 124M | 121M |
Other Countries | 10.2M | 15.12M | 16.28M | 21.97M | 27.24M |
Eliminations | -77.46M | -123M | -109M | -126M | -130M |
Executive Committee: BOIRON
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Houdayer
CEO | Chief Executive Officer | 57 | 2024-12-31 |
Frédéric Riou
CTO | Chief Tech/Sci/R&D Officer | - | - |
Isabelle Chanel
CTO | Chief Tech/Sci/R&D Officer | - | 2021-12-31 |
Hervé Coulpier
CTO | Chief Tech/Sci/R&D Officer | - | 2017-04-30 |
Patrice Varraut
COO | Chief Operating Officer | - | 2015-12-31 |
Composition of the Board of Directors: BOIRON
| Director | Title | Age | Since |
|---|---|---|---|
Thierry Boiron
CHM | Chairman | 65 | 2011-06-30 |
Jean-Marc Chalot
BRD | Director/Board Member | 67 | 2022-05-18 |
Philippe Brun
BRD | Director/Board Member | 66 | 2021-05-26 |
| Director/Board Member | 54 | 2010-03-09 | |
| Director/Board Member | 51 | 2013-05-22 | |
Pascal Houdayer
BRD | Director/Board Member | 57 | 2024-12-31 |
Evis Hursever
BRD | Director/Board Member | - | 2023-10-19 |
Grégory Walter
BRD | Director/Board Member | 48 | 2017-05-17 |
Benjamin Boiron
BRD | Director/Board Member | 25 | 2023-10-19 |
Laurence Boiron
BRD | Director/Board Member | 51 | 2020-05-27 |
Holdings: BOIRON
| Name | Stocks | % | Valuation |
|---|---|---|---|
BOIRON 1.04% | 183,133 | 1.04% | 5 M $ |
Company details: BOIRON
Group companies: BOIRON
| Name | Category and Sector |
|---|---|
Boiron Laboratories Pvt Ltd. |
Alternative Medicine
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.75% | +0.76% | -27.82% | -63.04% | 388M | |
| -0.62% | -2.71% | +39.30% | +114.07% | 1,025B | |
| -2.30% | -4.44% | +39.03% | +66.07% | 623B | |
| -0.63% | -1.96% | +6.36% | +74.38% | 459B | |
| -1.03% | -2.82% | +59.56% | +39.69% | 355B | |
| -0.03% | -3.96% | +23.63% | +39.35% | 336B | |
| -1.58% | -0.76% | +13.50% | +25.77% | 270B | |
| -2.02% | -2.97% | -3.25% | +8.38% | 247B | |
| -3.38% | +0.30% | +36.44% | +51.54% | 220B | |
| -1.04% | -1.46% | +32.70% | +96.82% | 183B | |
| Average | -1.34% | -1.63% | +21.95% | +45.30% | 371.86B | |
| Weighted average by Cap. | -1.24% | -2.11% | +30.51% | +69.28% |
Sector
Annual profits - Rate of surprise
- Stock Market
- Stocks
- BOI Stock
- Company BOIRON
Select your edition
All financial news and data tailored to specific country editions
